Journal article · 2026
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
New England Journal of Medicine, 394(18), 1790–1802 · Published 6 May 2026 · DOI 10.1056/nejmoa2505783
In brief
“Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer” is a 2026 journal article by Brian Matthew Wolpin and 19 co-authors, published in New England Journal of Medicine. OpenAlex counts 129 citations as of 17 November 2026, which puts it in the top 7% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 129
- Most cited in
- 2026 (127)
- Field-weighted impact
- 286.41
- References
- 36
- Authors
- 20
Abstract
BackgroundCurrent therapies for patients with pancreatic ductal adenocarcinoma (PDAC) provide modest benefit. Activating RAS mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate–bound mutant and wild-type RAS. MethodsIn this phase 1–2 study, we evaluated daraxonrasib in patients with advanced solid tumors with activating… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Wolpin, B. M., Park, W., Garrido‐Laguna, I., Spira, A. I., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M. A., Pelster, M. S., Herzberg, B., Azad, N. S., Hecht, J. R., Ou, S. I., Lin, T., Kar, S., Tao, L., Vora, R., Hegde, A., Aung, K. L., & Hong, D. S. (2026). Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer. New England Journal of Medicine, 394(18), 1790–1802. https://doi.org/10.1056/nejmoa2505783
MLA 9
Wolpin, Brian Matthew, et al. “Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer.” New England Journal of Medicine, vol. 394, no. 18, 2026, pp. 1790–1802. https://doi.org/10.1056/nejmoa2505783.
Chicago
Wolpin, Brian Matthew, Wungki Park, Ignacio Garrido‐Laguna, Alexander I. Spira, Alexander Starodub, David Sommerhalder, Salman Rafi Punekar, et al. 2026. “Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer.” New England Journal of Medicine 394 (18): 1790–1802. https://doi.org/10.1056/nejmoa2505783.
Harvard
Wolpin, B. M. et al. (2026) ‘Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer’, New England Journal of Medicine, 394(18), pp. 1790–1802. doi:10.1056/nejmoa2505783.
IEEE
B. M. Wolpin et al., “Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer,” New England Journal of Medicine, vol. 394, no. 18, pp. 1790–1802, 2026, doi: 10.1056/nejmoa2505783.
BibTeX
@article{wolpin2026daraxonrasib,
title = {{Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer}},
author = {Wolpin, Brian Matthew and Park, Wungki and Garrido‐Laguna, Ignacio and Spira, Alexander I. and Starodub, Alexander and Sommerhalder, David and Punekar, Salman Rafi and Barve, Minal A. and Pelster, Meredith S. and Herzberg, Benjamin and Azad, Nilofer Saba and Hecht, Joel Randolph and Ou, Sai‐Hong Ignatius and Lin, Tong and Kar, Sumit and Tao, Lin and Vora, Rashmi and Hegde, Aparna and Aung, Kyaw Lwin and Hong, David S.},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {18},
pages = {1790--1802},
doi = {10.1056/nejmoa2505783},
url = {https://doi.org/10.1056/nejmoa2505783}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- daraxonrasib
- RMC-6236
- RAS inhibitors
- treatment-related adverse events
- anticancer activity
- oral targeted therapy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Wolpin, B. M., Park, W., Garrido‐Laguna, I., Spira, A. I., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M. A., Pelster, M. S., Herzberg, B., Azad, N. S., Hecht, J. R., Ou, S. I., Lin, T., Kar, S., Tao, L., Vora, R., Hegde, A., Aung, K. L., & Hong, D. S. (2026). Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer. New England Journal of Medicine, 394(18), 1790–1802. https://doi.org/10.1056/nejmoa2505783
How many times has this paper been cited?
129 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Brian Matthew Wolpin, Wungki Park, Ignacio Garrido‐Laguna, Alexander I. Spira, Alexander Starodub, David Sommerhalder, Salman Rafi Punekar, Minal A. Barve, Meredith S. Pelster, Benjamin Herzberg, Nilofer Saba Azad, Joel Randolph Hecht and 8 more.
What is the DOI of this paper?
10.1056/nejmoa2505783, permanently at https://doi.org/10.1056/nejmoa2505783. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.